Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Leukocytes01:27

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021.

JAMA network open·2022
Same author

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.

The New England journal of medicine·2016
Same author

Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition.

Nature communications·2016
Same author

Role of the tumor microenvironment in mature B-cell lymphoid malignancies.

Haematologica·2016
Same author

Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib.

Haematologica·2016
Same author

Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes.

British journal of haematology·2016

Related Experiment Video

Updated: May 29, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

Adverse prognostic features in chronic lymphocytic leukemia.

Sarah Schellhorn Mougalian1, Susan O'Brien

  • 1The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

Oncology (Williston Park, N.Y.)
|August 31, 2011
PubMed
Summary

Prognostic markers and cytogenetics significantly impact chronic lymphocytic leukemia (CLL) patient outcomes. Understanding these factors guides personalized treatment strategies for better survival and progression-free survival.

More Related Videos

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

Related Experiment Videos

Last Updated: May 29, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Chronic lymphocytic leukemia (CLL) exhibits variable clinical courses.
  • Rai and Binet staging systems historically classified CLL prognosis.
  • Novel prognostic markers and cytogenetic abnormalities offer deeper insights.

Purpose of the Study:

  • To review current prognostic markers and cytogenetic findings in CLL.
  • To correlate these factors with disease progression and treatment response.
  • To inform personalized treatment approaches for CLL patients.

Main Methods:

  • Review of established and emerging prognostic indicators in CLL.
  • Analysis of cytogenetic abnormalities, including del(17p), del(11q), trisomy 12, and del(6q).
  • Correlation of genetic markers (TP53, ATM) with clinical outcomes.

Main Results:

  • Elevated serum beta2M, TK, ZAP-70, CD38, and unmutated IgV(H) predict shorter progression and treatment times.
  • Del(17p) and TP53 mutations indicate aggressive disease and poor survival.
  • Del(11q) is linked to shorter progression-free survival; ATM mutations may also be adverse.
  • Trisomy 12 and del(6q) represent intermediate-risk cytogenetics.

Conclusions:

  • Cytogenetic abnormalities like del(17p) warrant evaluation for novel agents or stem cell transplantation.
  • Del(11q) necessitates specific chemoimmunotherapy regimens.
  • Trisomy 12 may enhance susceptibility to CD20-targeted therapies.
  • Continued research is crucial for refining prognostication and treatment in CLL.